Trial Outcomes & Findings for Evaluating Anti-Tobacco Message Effectiveness Among Lesbian, Gay, Bisexual, and Transgender Young Adults (NCT NCT05393869)
NCT ID: NCT05393869
Last Updated: 2023-12-26
Results Overview
6 items measured on 5-point scale, 1 = Not at all and 5 = Very much * These messages were worth remembering. * These messages grabbed my attention. * These messages are powerful. * These messages are convincing. * These messages are meaningful. * These messages are informative. Responses were summed and averaged to create a scale for intention to quit (range from 1 - 5). Higher scores indicate a higher persuasive potential of the message.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
2849 participants
Primary outcome timeframe
Immediately post-exposure to intervention, up to 1 hour
Results posted on
2023-12-26
Participant Flow
Participant milestones
| Measure |
AR-Quit
Participants view messages with absolute risk and quit statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
AR-Switch
Participants view messages with absolute risk and switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
AR-Combination
Participants view messages with absolute risk and combination quit+switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Quit
Participants view messages with comparative risk and quit statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Switch
Participants view messages with comparative risk and switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Combination
Participants view messages with comparative risk and combination quit+switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
Control
Participants view FDA regulatory messages
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
407
|
407
|
407
|
407
|
407
|
407
|
407
|
|
Overall Study
COMPLETED
|
400
|
405
|
398
|
404
|
402
|
403
|
404
|
|
Overall Study
NOT COMPLETED
|
7
|
2
|
9
|
3
|
5
|
4
|
3
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Evaluating Anti-Tobacco Message Effectiveness Among Lesbian, Gay, Bisexual, and Transgender Young Adults
Baseline characteristics by cohort
| Measure |
AR-Quit
n=407 Participants
Participants view messages with absolute risk and quit statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
AR-Switch
n=407 Participants
Participants view messages with absolute risk and switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
AR-Combination
n=407 Participants
Participants view messages with absolute risk and combination quit+switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Quit
n=407 Participants
Participants view messages with comparative risk and quit statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Switch
n=407 Participants
Participants view messages with comparative risk and switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Combination
n=407 Participants
Participants view messages with comparative risk and combination quit+switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
Control
n=407 Participants
Participants view FDA regulatory messages
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
Total
n=2849 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|
|
Dual smoking/vaping status
Only ever vaped nicotine OR smoked cigarettes
|
76 Participants
n=5 Participants
|
69 Participants
n=7 Participants
|
78 Participants
n=5 Participants
|
86 Participants
n=4 Participants
|
73 Participants
n=21 Participants
|
75 Participants
n=10 Participants
|
77 Participants
n=115 Participants
|
534 Participants
n=24 Participants
|
|
Age, Customized
18-24 years old
|
131 Participants
n=5 Participants
|
123 Participants
n=7 Participants
|
138 Participants
n=5 Participants
|
126 Participants
n=4 Participants
|
133 Participants
n=21 Participants
|
139 Participants
n=10 Participants
|
138 Participants
n=115 Participants
|
928 Participants
n=24 Participants
|
|
Age, Customized
25-35 years old
|
270 Participants
n=5 Participants
|
283 Participants
n=7 Participants
|
261 Participants
n=5 Participants
|
278 Participants
n=4 Participants
|
270 Participants
n=21 Participants
|
265 Participants
n=10 Participants
|
267 Participants
n=115 Participants
|
1894 Participants
n=24 Participants
|
|
Age, Customized
Unknown or not reported
|
6 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
8 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
3 Participants
n=10 Participants
|
2 Participants
n=115 Participants
|
27 Participants
n=24 Participants
|
|
Sex/Gender, Customized
Cisgender female
|
195 Participants
n=5 Participants
|
192 Participants
n=7 Participants
|
195 Participants
n=5 Participants
|
187 Participants
n=4 Participants
|
224 Participants
n=21 Participants
|
187 Participants
n=10 Participants
|
185 Participants
n=115 Participants
|
1365 Participants
n=24 Participants
|
|
Sex/Gender, Customized
Cisgender Male
|
169 Participants
n=5 Participants
|
183 Participants
n=7 Participants
|
163 Participants
n=5 Participants
|
179 Participants
n=4 Participants
|
152 Participants
n=21 Participants
|
171 Participants
n=10 Participants
|
180 Participants
n=115 Participants
|
1197 Participants
n=24 Participants
|
|
Sex/Gender, Customized
Transgender or gender diverse
|
36 Participants
n=5 Participants
|
30 Participants
n=7 Participants
|
41 Participants
n=5 Participants
|
38 Participants
n=4 Participants
|
27 Participants
n=21 Participants
|
46 Participants
n=10 Participants
|
40 Participants
n=115 Participants
|
258 Participants
n=24 Participants
|
|
Sex/Gender, Customized
Unknown or not reported
|
7 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
8 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
3 Participants
n=10 Participants
|
2 Participants
n=115 Participants
|
29 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
58 Participants
n=5 Participants
|
59 Participants
n=7 Participants
|
49 Participants
n=5 Participants
|
57 Participants
n=4 Participants
|
45 Participants
n=21 Participants
|
62 Participants
n=10 Participants
|
48 Participants
n=115 Participants
|
378 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
343 Participants
n=5 Participants
|
347 Participants
n=7 Participants
|
350 Participants
n=5 Participants
|
347 Participants
n=4 Participants
|
358 Participants
n=21 Participants
|
342 Participants
n=10 Participants
|
357 Participants
n=115 Participants
|
2444 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
6 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
8 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
3 Participants
n=10 Participants
|
2 Participants
n=115 Participants
|
27 Participants
n=24 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
3 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
4 Participants
n=10 Participants
|
2 Participants
n=115 Participants
|
22 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Asian
|
30 Participants
n=5 Participants
|
39 Participants
n=7 Participants
|
28 Participants
n=5 Participants
|
43 Participants
n=4 Participants
|
31 Participants
n=21 Participants
|
36 Participants
n=10 Participants
|
31 Participants
n=115 Participants
|
238 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
2 Participants
n=115 Participants
|
5 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Black or African American
|
47 Participants
n=5 Participants
|
41 Participants
n=7 Participants
|
45 Participants
n=5 Participants
|
39 Participants
n=4 Participants
|
42 Participants
n=21 Participants
|
55 Participants
n=10 Participants
|
53 Participants
n=115 Participants
|
322 Participants
n=24 Participants
|
|
Race (NIH/OMB)
White
|
253 Participants
n=5 Participants
|
256 Participants
n=7 Participants
|
258 Participants
n=5 Participants
|
246 Participants
n=4 Participants
|
266 Participants
n=21 Participants
|
244 Participants
n=10 Participants
|
264 Participants
n=115 Participants
|
1787 Participants
n=24 Participants
|
|
Race (NIH/OMB)
More than one race
|
24 Participants
n=5 Participants
|
24 Participants
n=7 Participants
|
29 Participants
n=5 Participants
|
32 Participants
n=4 Participants
|
32 Participants
n=21 Participants
|
27 Participants
n=10 Participants
|
16 Participants
n=115 Participants
|
184 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
50 Participants
n=5 Participants
|
45 Participants
n=7 Participants
|
42 Participants
n=5 Participants
|
43 Participants
n=4 Participants
|
31 Participants
n=21 Participants
|
41 Participants
n=10 Participants
|
39 Participants
n=115 Participants
|
291 Participants
n=24 Participants
|
|
Region of Enrollment
United States
|
407 participants
n=5 Participants
|
407 participants
n=7 Participants
|
407 participants
n=5 Participants
|
407 participants
n=4 Participants
|
407 participants
n=21 Participants
|
407 participants
n=10 Participants
|
407 participants
n=115 Participants
|
2849 participants
n=24 Participants
|
|
Sexual Orientation
Heterosexual
|
206 Participants
n=5 Participants
|
225 Participants
n=7 Participants
|
200 Participants
n=5 Participants
|
215 Participants
n=4 Participants
|
215 Participants
n=21 Participants
|
220 Participants
n=10 Participants
|
212 Participants
n=115 Participants
|
1493 Participants
n=24 Participants
|
|
Sexual Orientation
Lesbian or gay
|
46 Participants
n=5 Participants
|
43 Participants
n=7 Participants
|
38 Participants
n=5 Participants
|
45 Participants
n=4 Participants
|
37 Participants
n=21 Participants
|
46 Participants
n=10 Participants
|
44 Participants
n=115 Participants
|
299 Participants
n=24 Participants
|
|
Sexual Orientation
Bisexual
|
129 Participants
n=5 Participants
|
121 Participants
n=7 Participants
|
131 Participants
n=5 Participants
|
126 Participants
n=4 Participants
|
141 Participants
n=21 Participants
|
124 Participants
n=10 Participants
|
133 Participants
n=115 Participants
|
905 Participants
n=24 Participants
|
|
Sexual Orientation
Ace/Asexual
|
19 Participants
n=5 Participants
|
17 Participants
n=7 Participants
|
29 Participants
n=5 Participants
|
16 Participants
n=4 Participants
|
10 Participants
n=21 Participants
|
13 Participants
n=10 Participants
|
14 Participants
n=115 Participants
|
118 Participants
n=24 Participants
|
|
Sexual Orientation
Unknown or not reported
|
7 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
9 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
4 Participants
n=10 Participants
|
4 Participants
n=115 Participants
|
34 Participants
n=24 Participants
|
|
Smoking status
Currently use cigarettes
|
108 Participants
n=5 Participants
|
114 Participants
n=7 Participants
|
106 Participants
n=5 Participants
|
106 Participants
n=4 Participants
|
93 Participants
n=21 Participants
|
106 Participants
n=10 Participants
|
117 Participants
n=115 Participants
|
750 Participants
n=24 Participants
|
|
Smoking status
Formerly used cigarettes
|
168 Participants
n=5 Participants
|
148 Participants
n=7 Participants
|
176 Participants
n=5 Participants
|
170 Participants
n=4 Participants
|
192 Participants
n=21 Participants
|
171 Participants
n=10 Participants
|
159 Participants
n=115 Participants
|
1184 Participants
n=24 Participants
|
|
Smoking status
Never used cigarettes
|
131 Participants
n=5 Participants
|
145 Participants
n=7 Participants
|
125 Participants
n=5 Participants
|
131 Participants
n=4 Participants
|
122 Participants
n=21 Participants
|
130 Participants
n=10 Participants
|
131 Participants
n=115 Participants
|
915 Participants
n=24 Participants
|
|
Smoking status
Unknown or not reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=24 Participants
|
|
Vaping status
Currently vape nicotine
|
141 Participants
n=5 Participants
|
144 Participants
n=7 Participants
|
146 Participants
n=5 Participants
|
137 Participants
n=4 Participants
|
160 Participants
n=21 Participants
|
147 Participants
n=10 Participants
|
140 Participants
n=115 Participants
|
1015 Participants
n=24 Participants
|
|
Vaping status
Formerly vaped nicotine
|
139 Participants
n=5 Participants
|
133 Participants
n=7 Participants
|
132 Participants
n=5 Participants
|
141 Participants
n=4 Participants
|
118 Participants
n=21 Participants
|
117 Participants
n=10 Participants
|
135 Participants
n=115 Participants
|
915 Participants
n=24 Participants
|
|
Vaping status
Never vaped nicotine
|
127 Participants
n=5 Participants
|
130 Participants
n=7 Participants
|
129 Participants
n=5 Participants
|
129 Participants
n=4 Participants
|
129 Participants
n=21 Participants
|
143 Participants
n=10 Participants
|
132 Participants
n=115 Participants
|
919 Participants
n=24 Participants
|
|
Vaping status
Unknown or not reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=24 Participants
|
|
Dual smoking/vaping status
Currently vape nicotine AND smoke cigarettes
|
63 Participants
n=5 Participants
|
73 Participants
n=7 Participants
|
65 Participants
n=5 Participants
|
57 Participants
n=4 Participants
|
61 Participants
n=21 Participants
|
64 Participants
n=10 Participants
|
69 Participants
n=115 Participants
|
452 Participants
n=24 Participants
|
|
Dual smoking/vaping status
Formerly vaped nicotine AND smoked cigarettes
|
177 Participants
n=5 Participants
|
162 Participants
n=7 Participants
|
176 Participants
n=5 Participants
|
177 Participants
n=4 Participants
|
184 Participants
n=21 Participants
|
169 Participants
n=10 Participants
|
168 Participants
n=115 Participants
|
1213 Participants
n=24 Participants
|
|
Dual smoking/vaping status
Never vaped nicotine OR smoked cigarettes
|
91 Participants
n=5 Participants
|
103 Participants
n=7 Participants
|
88 Participants
n=5 Participants
|
87 Participants
n=4 Participants
|
89 Participants
n=21 Participants
|
99 Participants
n=10 Participants
|
93 Participants
n=115 Participants
|
650 Participants
n=24 Participants
|
|
Dual smoking/vaping status
Unknown or not reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=24 Participants
|
PRIMARY outcome
Timeframe: Immediately post-exposure to intervention, up to 1 hourPopulation: Analytic population only included participants who had no missing data for any scale items.
6 items measured on 5-point scale, 1 = Not at all and 5 = Very much * These messages were worth remembering. * These messages grabbed my attention. * These messages are powerful. * These messages are convincing. * These messages are meaningful. * These messages are informative. Responses were summed and averaged to create a scale for intention to quit (range from 1 - 5). Higher scores indicate a higher persuasive potential of the message.
Outcome measures
| Measure |
AR-Quit
n=399 Participants
Participants view messages with absolute risk and quit statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
AR-Switch
n=402 Participants
Participants view messages with absolute risk and switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
AR-Combination
n=396 Participants
Participants view messages with absolute risk and combination quit+switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Quit
n=403 Participants
Participants view messages with comparative risk and quit statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Switch
n=401 Participants
Participants view messages with comparative risk and switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Combination
n=402 Participants
Participants view messages with comparative risk and combination quit+switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
Control
n=402 Participants
Participants view FDA regulatory messages
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
|---|---|---|---|---|---|---|---|
|
Message Perceived Effectiveness - Persuasive Potential.
|
3.57 units on a scale
Interval 3.47 to 3.67
|
3.24 units on a scale
Interval 3.13 to 3.35
|
3.26 units on a scale
Interval 3.15 to 3.36
|
3.44 units on a scale
Interval 3.33 to 3.54
|
2.93 units on a scale
Interval 2.42 to 3.44
|
2.98 units on a scale
Interval 2.48 to 3.49
|
3.10 units on a scale
Interval 2.96 to 3.24
|
PRIMARY outcome
Timeframe: Immediately post-exposure to intervention, up to 1 hourPopulation: Analytic population did not include participants with missing data for outcomes.
Six items were analyzed separately, each scored on 5-point Likert scale (1=Strongly Disagree, 5=Strongly Agree) These messages will motivate CIGARETTE SMOKERS to switch to vaping. These messages will motivate people to quit ALL smoking and vaping. These messages will motivate NON-USERS to start vaping. These messages will motivate NON-USERS to start smoking cigarettes. These messages will motivate CIGARETTE SMOKERS to quit. These messages will motivate VAPERS to quit.
Outcome measures
| Measure |
AR-Quit
n=403 Participants
Participants view messages with absolute risk and quit statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
AR-Switch
n=407 Participants
Participants view messages with absolute risk and switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
AR-Combination
n=399 Participants
Participants view messages with absolute risk and combination quit+switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Quit
n=405 Participants
Participants view messages with comparative risk and quit statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Switch
n=403 Participants
Participants view messages with comparative risk and switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Combination
n=405 Participants
Participants view messages with comparative risk and combination quit+switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
Control
n=405 Participants
Participants view FDA regulatory messages
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
|---|---|---|---|---|---|---|---|
|
Perceived Effectiveness - Perceived Behavioral Impact
These messages will motivate NON-USERS to start vaping.
|
1.26 units on a scale
Interval 1.2 to 1.33
|
1.91 units on a scale
Interval 1.8 to 2.02
|
1.87 units on a scale
Interval 1.75 to 1.98
|
1.62 units on a scale
Interval 1.53 to 1.72
|
2.17 units on a scale
Interval 2.05 to 2.29
|
2.14 units on a scale
Interval 2.02 to 2.26
|
1.26 units on a scale
Interval 1.2 to 1.33
|
|
Perceived Effectiveness - Perceived Behavioral Impact
These messages will motivate people to quit ALL smoking and vaping.
|
2.96 units on a scale
Interval 2.84 to 3.08
|
2.38 units on a scale
Interval 2.25 to 2.5
|
2.44 units on a scale
Interval 2.32 to 2.56
|
2.71 units on a scale
Interval 2.59 to 2.84
|
2.07 units on a scale
Interval 1.96 to 2.19
|
2.22 units on a scale
Interval 2.11 to 2.34
|
2.76 units on a scale
Interval 2.63 to 2.88
|
|
Perceived Effectiveness - Perceived Behavioral Impact
These messages will motivate CIGARETTE SMOKERS to quit.
|
3.11 units on a scale
Interval 2.97 to 3.23
|
3.10 units on a scale
Interval 2.98 to 3.22
|
3.16 units on a scale
Interval 3.04 to 3.27
|
3.28 units on a scale
Interval 3.17 to 3.4
|
3.00 units on a scale
Interval 2.88 to 3.11
|
3.17 units on a scale
Interval 3.04 to 3.29
|
2.82 units on a scale
Interval 2.7 to 2.95
|
|
Perceived Effectiveness - Perceived Behavioral Impact
These messages will motivate CIGARETTE SMOKERS to switch to vaping
|
2.10 units on a scale
Interval 2.0 to 2.21
|
3.52 units on a scale
Interval 3.4 to 3.63
|
3.41 units on a scale
Interval 3.29 to 3.53
|
3.34 units on a scale
Interval 3.22 to 3.45
|
3.67 units on a scale
Interval 3.57 to 3.78
|
3.67 units on a scale
Interval 3.56 to 3.78
|
1.81 units on a scale
Interval 1.72 to 1.91
|
|
Perceived Effectiveness - Perceived Behavioral Impact
These messages will motivate VAPERS to quit.
|
2.96 units on a scale
Interval 2.84 to 3.08
|
2.21 units on a scale
Interval 2.09 to 2.33
|
2.26 units on a scale
Interval 2.14 to 2.37
|
2.53 units on a scale
Interval 2.41 to 2.64
|
1.84 units on a scale
Interval 1.73 to 1.94
|
1.94 units on a scale
Interval 1.83 to 2.04
|
2.83 units on a scale
Interval 2.71 to 2.95
|
|
Perceived Effectiveness - Perceived Behavioral Impact
These messages will motivate NON-USERS to start smoking cigarettes.
|
1.24 units on a scale
Interval 1.17 to 1.3
|
1.29 units on a scale
Interval 1.22 to 1.36
|
1.35 units on a scale
Interval 1.27 to 1.42
|
1.21 units on a scale
Interval 1.15 to 1.27
|
1.30 units on a scale
Interval 1.23 to 1.37
|
1.32 units on a scale
Interval 1.25 to 1.4
|
1.24 units on a scale
Interval 1.18 to 1.3
|
PRIMARY outcome
Timeframe: Immediately post-exposure to intervention, up to 1 hourPopulation: Analytic population included participants with no missing data on outcomes.
On a scale from 0-10, where 0 = not at all harmful and 10 = extremely harmful now harmful are ... to your health? * combustible cigarettes * nicotine vapes On a scale from 0-10, where 0 = much less harmful and 10 = much more harmful... • compared to combustible cigarettes, how harmful are nicotine vapes to your health?
Outcome measures
| Measure |
AR-Quit
n=399 Participants
Participants view messages with absolute risk and quit statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
AR-Switch
n=402 Participants
Participants view messages with absolute risk and switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
AR-Combination
n=396 Participants
Participants view messages with absolute risk and combination quit+switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Quit
n=403 Participants
Participants view messages with comparative risk and quit statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Switch
n=402 Participants
Participants view messages with comparative risk and switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Combination
n=402 Participants
Participants view messages with comparative risk and combination quit+switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
Control
n=403 Participants
Participants view FDA regulatory messages
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
|---|---|---|---|---|---|---|---|
|
Risk Perceptions: Absolute/Relative Risks of Cigarette vs. E-cigarette Use
Absolute harm of cigarettes to health
|
9.08 units on a scale
Interval 8.95 to 9.21
|
9.07 units on a scale
Interval 8.93 to 9.21
|
8.97 units on a scale
Interval 8.82 to 9.12
|
9.11 units on a scale
Interval 8.98 to 9.24
|
9.06 units on a scale
Interval 8.93 to 9.2
|
9.04 units on a scale
Interval 8.89 to 9.19
|
8.94 units on a scale
Interval 8.79 to 9.09
|
|
Risk Perceptions: Absolute/Relative Risks of Cigarette vs. E-cigarette Use
Absolute harm of nicotine vapes to health
|
7.57 units on a scale
Interval 7.35 to 7.79
|
7.05 units on a scale
Interval 6.83 to 7.27
|
7.19 units on a scale
Interval 6.96 to 7.42
|
7.19 units on a scale
Interval 6.97 to 7.42
|
6.88 units on a scale
Interval 6.64 to 7.11
|
6.94 units on a scale
Interval 6.71 to 7.17
|
7.57 units on a scale
Interval 7.34 to 7.8
|
|
Risk Perceptions: Absolute/Relative Risks of Cigarette vs. E-cigarette Use
Relative harm of nicotine vapes (vs combustible cigarettes) to health
|
4.99 units on a scale
Interval 4.71 to 5.26
|
4.65 units on a scale
Interval 4.38 to 4.92
|
4.81 units on a scale
Interval 4.51 to 5.11
|
4.46 units on a scale
Interval 4.16 to 4.75
|
4.34 units on a scale
Interval 4.05 to 4.64
|
4.49 units on a scale
Interval 4.2 to 4.78
|
5.04 units on a scale
Interval 4.77 to 5.3
|
PRIMARY outcome
Timeframe: Immediately post-exposure to intervention, up to 1 hourPopulation: Analytic population included participants who did not have missing data on outcomes.
8-items made up two 4-pt scales (1 = definitely will not and 4 = definitely will). Items for each scale were summed and averaged. Higher scores indicate higher likelihood of avoiding cigarettes/nicotine vapes. How likely it is that in the next 3 months, you will refrain from... * smoking cigarettes completely and permanently? * smoking cigarettes when you get lonely? * smoking cigarettes when you are with your friends who use them? * smoking cigarettes when someone hands you a cigarette? How likely it is that in the next 3 months, you will refrain from... * vaping nicotine completely and permanently? * vaping nicotine when you get lonely? * vaping nicotine when you are with your friends who use them? * vaping nicotine when someone hands you a vape?
Outcome measures
| Measure |
AR-Quit
n=403 Participants
Participants view messages with absolute risk and quit statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
AR-Switch
n=407 Participants
Participants view messages with absolute risk and switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
AR-Combination
n=399 Participants
Participants view messages with absolute risk and combination quit+switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Quit
n=405 Participants
Participants view messages with comparative risk and quit statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Switch
n=403 Participants
Participants view messages with comparative risk and switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
RR-Combination
n=405 Participants
Participants view messages with comparative risk and combination quit+switch statements
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
Control
n=405 Participants
Participants view FDA regulatory messages
Health communications: Participants are assigned to view health communications with risk and efficacy statements.
|
|---|---|---|---|---|---|---|---|
|
Behavioral Intentions to Use Tobacco
Behavioral intentions to use nicotine vapes
|
3.27 units on a scale
Interval 3.17 to 3.36
|
3.16 units on a scale
Interval 3.06 to 3.26
|
3.16 units on a scale
Interval 3.06 to 3.27
|
3.22 units on a scale
Interval 3.12 to 3.31
|
3.11 units on a scale
Interval 3.01 to 3.22
|
3.17 units on a scale
Interval 3.07 to 3.27
|
3.15 units on a scale
Interval 3.04 to 3.25
|
|
Behavioral Intentions to Use Tobacco
Behavioral intentions to smoke cigarettes
|
3.48 units on a scale
Interval 3.4 to 3.56
|
3.40 units on a scale
Interval 3.31 to 3.49
|
3.40 units on a scale
Interval 3.3 to 3.49
|
3.46 units on a scale
Interval 3.37 to 3.54
|
3.46 units on a scale
Interval 3.38 to 3.55
|
3.44 units on a scale
Interval 3.35 to 3.52
|
3.37 units on a scale
Interval 3.28 to 3.46
|
Adverse Events
AR-Quit
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
AR-Switch
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
AR-Combination
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
RR-Quit
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
RR-Switch
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
RR-Combination
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Control
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Joanne G. Patterson
The Ohio State University College of Public Health
Phone: 614-247-1780
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place